CSBio CSBio

X
[{"orgOrder":0,"company":"Lucis Pharma","sponsor":"Rosemont","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rosemont Expands its Offering with Portfolio Acquisition from Lucis Pharma Ltd","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Lucis Pharma"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Through the acquisition, Rosemont will expand its existing portfolio and have access to a pipeline of innovative products including, alimemazine tartrate, an oral solution, used for the management of urticaria and pruritus.

            Lead Product(s): Alimemazine

            Therapeutic Area: Dermatology Product Name: Alimemazine Tartrate-Generic

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Rosemont

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition June 16, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY